$SPRCMay 28, 2026, 12:40 PMAI processed
NeuroThera/SciSparc gets conditional TSXV approval to buy ~54% of CliniQuantum
AI Summary
NeuroThera Labs (majority‐owned by SciSparc) received conditional TSX Venture approval to acquire ~54% of CliniQuantum in exchange for 56.6M NeuroThera shares (valued at ~ $9.46M based on a 20‐day VWAP). CliniQuantum's primary asset is an exclusive license to a US provisional patent for quantum simulation/quantum Monte Carlo methods aimed at improving clinical trial subgroup identification; closing remains conditional on an Israeli tax ruling and final TSX acceptance, and the Consideration Shares will be placed in escrow with lock‐ups and an earn‐out share floor of $0.05.
Positives
- TSX Venture provided conditional approval for the acquisition of ~54% of CliniQuantum
- Deal consideration is 56.6M NeuroThera shares (~$9.46M based on 20‑day VWAP), making the transaction size explicit
- Consideration Shares will be escrowed and Selling Shareholders have executed lock‑ups per TSX policies
Negatives
- Approval is conditional — closing depends on obtaining an Israeli tax ruling and final TSX acceptance
- CliniQuantum's core IP is a single U.S. provisional patent application, representing early‑stage IP risk
- An earn‑out share issuance floor of $0.05 (set to meet TSX rules) could still dilute existing holders if earn‑outs are triggered